The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,002
Matsumoto, S., Henderson, A. D., Shen, L., Kondo, T., Yang, M., Campbell, R. T., Anand, I. S., de Boer, R. A., Desai, A. S., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3383 · Cited by 25
Self-citationQuiriarte, H. D., Noland, R. C., Stampley, J., Davis, G., Li, Z., Cho, E., Kim, Y., Doiron, J. E., Spielmann, G., Ghosh, S. K., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.07.009 · Cited by 24
Self-citationDiabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies
Rizza, V., Tondi, L., Patti, A. M., Cecchi, D., Lombardi, M., Perone, F., Ambrosetti, M., Rizzo, M., Cianflone, D., & Maranta, F. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200338 · Cited by 29
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors
Katsimardou, A., Theofilis, P., Vordoni, A., Doumas, M. N., & Kalaitzidis, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212384 · Cited by 29
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25
Li, R., Liu, Y., Zhao, Z., Zhang, C., Dong, W., Yu, Q., Gao, J., Gu, F., Carlson, B. E., Beard, D. A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103462 · Cited by 31
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 33
Rong, X., Zhu, Y., Bo, W., Liu, K., Li, X., Gou, Q., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.973129 · Cited by 27
Fauvel, C., Bonnet, G., Müllens, W., Giraldo, C. I. S., Mežnar, A. Z., Barasa, A. L., Tokmakova, M. P., Shchendrygina, A., Costa, F. M., Mapelli, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2743 · Cited by 24
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0047 · Cited by 23
Optimizing Outcomes in Heart Failure: 2022 and Beyond
Jankowska, E. A., Andersson, T., Kaiser‐Albers, C., Bozkurt, B., Chioncel, O. D., Coats, A. J. S., Hill, L., Koehler, F., Lund, L. H., McDonagh, T. A., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14363 · Cited by 25
Self-citationChatur, S., Cunningham, J. W., Vaduganathan, M., Causland, F. R. M., Claggett, B. L., Desai, A. S., Miao, Z. M., Jhund, P. S., de Boer, R. A., Hernandez, A. F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2915 · Cited by 23
Self-citationMarcos, M. C., de la Espriella, R., Ordás, J. G., Llàcer, P., Pomares, A., Fort, A., de Antonio, I. P., Méndez, A. B., Blázquez‐Bermejo, Z., Pérez, P. C., et al. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.05.004 · Cited by 24
Zhao, Z., Wang, Y., Jiang, C., Yang, Z., Zhang, J., Lai, Y., Wang, J., Li, S., Peng, X., Li, M., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.034 · Cited by 23
Armentaro, G., Pelaia, C., Condoleo, V., Severini, G., Crudo, G., Marco, M. D., Pastura, C. A., Tallarico, V., Pezzella, R., Aiello, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050937 · Cited by 22
Wang, M., Liu, X., Ding, B., Lu, Q., & Ma, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116994 · Cited by 22
Competing Risks in Clinical Trials
Gregson, J., Pocock, S., Anker, S. D., Bhatt, D. L., Packer, M., Stone, G. W., & Zeller, C. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.023 · Cited by 22
Zhang, W., Wang, L., Wang, Y., Fang, Y., Cao, R., Fang, Z., Han, D. G., Huang, X., Gu, Z., Zhang, Y., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2602-7 · Cited by 22
Diabetic Cardiomyopathy: What Clinicians Should Know
Smati, H., Qadeer, Y. K., Rodríguez, M., Moras, E., Fonarow, G. C., Isaacs, S. D., Marwick, T. H., & Krittanawong, C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.10.026 · Cited by 24
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 23
Self-citationRasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 26
Menghoum, N., Badii, M. C., Leroy, M., Parra, M., Roy, C., Lejeune, S., Vancraeynest, D., Pasquet, A., Brito, D. A., Casadei, B., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02688-7 · Cited by 25
Taylor, E. B., Hall, J. E., & Mouton, A. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107761 · Cited by 25
Maddaloni, E., Cavallari, I., Porta, Y. L., Appetecchia, A., D’Onofrio, L., Grigioni, F., Buzzetti, R., & Holman, R. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14986 · Cited by 25
The controversial role of beta-blockers in heart failure with preserved ejection fraction
Wernhart, S., Παπαθανασίου, Μ., Rassaf, T., & Luedike, P. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108356 · Cited by 23
Sanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 24
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Ashfaq, A., Meineck, M., Pautz, A., Arioglu‐Inan, E., Weinmann‐Menke, J., & Michel, M. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108503 · Cited by 23
SGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 24
Mizobuchi, S., Saito, Y., Kitano, D., Toyama, K., Miyagawa, M., Koyama, Y., Fujito, H., Kojima, K., Murata, N., Fukamachi, D., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14597 · Cited by 22
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Connelly, K. A., O’Meara, E., Zieroth, S. R., & Sherifali, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02154-w · Cited by 23
Self-citationGallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23
Pouleur, A., Menghoum, N., Cumps, J., Marino, A., Badii, M. C., Lejeune, S., Legault, J. T., Boucher, G., Gruson, D., Roy, C., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105264 · Cited by 23
Kondo, T., Jhund, P. S., Gasparyan, S. B., Yang, M., Claggett, B. L., McCausland, F. R., Tolomeo, P., Vadagunathan, M., Heerspink, H. J. L., Solomon, S. D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02941-8 · Cited by 25
Self-citationThe long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
McEwan, P. C., Gabb, P. D., Davis, J. A., Sánchez, J. J. G., Sjöström, C. D., Barone, S., Kashioulis, P., Ouwens, M., Cassimaty, S., Correa‐Rotter, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae106 · Cited by 21
Piperis, C., Marathonitis, A., Anastasiou, A., Theofilis, P., Mourouzis, K., Giannakodimos, A., Tryfou, E. S., Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12102314 · Cited by 26
Martinez, C. S., Zheng, A., & Xiao, Q. (2024) · Antioxidants · doi:10.3390/antiox13111330 · Cited by 26
Berger, J. H., Shi, Y., Matsuura, T. R., Batmanov, K., Chen, X., Tam, K., Marshall, M., Kue, R., Patel, J. D., Taing, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84515-9 · Cited by 22
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Self-citationZile, M. R., Abraham, W. T., Stevenson, L. W., Costanzo, M. R., Angermann, C. E., Mehra, M. R., Desai, A. S., Ducharme, A., Johnson, N., Henderson, J., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012754 · Cited by 26
Self-citationKaneko, T., Kagiyama, N., Okazaki, S., Amano, M., Satô, Y., Ohno, Y., Obokata, M., Sato, K., Morita, K., Kubo, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf511 · Cited by 21
SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases
Checa-Ros, A., Okojie, O.-J., & D’Marco, L. (2025) · Metabolites · doi:10.3390/metabo15080536 · Cited by 23
Hacil, A., Antakly, Y., Lacour, A., David, J.-P., Khalifa, T., Piccoli, M., Clemencin, A., Assayag, P., Vidal, J., & Hanon, O. (2025) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag193.770 · Cited by 22
Leo, I., Salerno, N., Figliozzi, S., Cersosimo, A., Ielapi, J., Stankowski, K., Bisaccia, G., Dellegrottaglie, S., Canino, G., Rosa, S. D., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02904-4 · Cited by 22
Wybraniec, M. T., Orszulak, M., Męcka, K., & Mizia‐Stec, K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114400 · Cited by 22
Dago, M., Crespo‐García, T., Cámara‐Checa, A., Rapún, J., Rubio‐Alarcón, M., Marín, M., Tamargo, J. L., Caballero, R., & Delpón, E. (2022) · Cells · doi:10.3390/cells11233707 · Cited by 21
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Kearney, J., & Gnudi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051343 · Cited by 22
How to recognize a trustworthy clinical practice guideline
Lima, J. P., Mirza, R. D., & Guyatt, G. H. (2023) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-023-00094-7 · Cited by 21
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Gotzmann, M., Henk, P., Stervbo, U., Blazquez‐Navarro, A., Mügge, A., Babel, N., & Westhoff, T. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134458 · Cited by 21
Park, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0016 · Cited by 21
Albuminuria in Transthyretin Cardiac Amyloidosis: Prevalence, Progression and Prognostic Importance
Ioannou, A., Rauf, M. U., Patel, R. K., Razvi, Y., Porcari, A., Martinez–Naharro, A., Venneri, L., Bandera, F., Virsinskaite, R., Kotecha, T., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3094 · Cited by 20
Self-citationRodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up
Zamora, E., Codina, P., Aimo, A., Lupón, J., Domingo, M., Troya, M. I., Santiago‐Vacas, E., Cediel, G., Borrellas, A., Ruiz-Cueto, M., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.004 · Cited by 21
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Mónica Acevedo, B., Samuel Córdova, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 25
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Chatzianagnostou, K., Gaggini, M., Suman, A. F., Simonini, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116218 · Cited by 20
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF
Gustafsson, F., Petrie, M. C., Komtebedde, J., Swarup, V., Winkler, S., Hasenfuss, G. P., Borlaug, B. A., Mohan, R. C., Flaherty, J. D., Sverdlov, A. L., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.011 · Cited by 21
Self-citationMahmood, A., Dhall, E., Primus, C., Gallagher, A. M., Zakeri, R., Mohammed, S. F., Chahal, C. A. A., Ricci, F., Aung, N., & Khanji, M. Y. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae053 · Cited by 29
Kocabaş, U., Ergin, I., Yavuz, V., Altın, C., Kaplan, M., Öztekin, G. M. Y., Doğduş, M., Murat, S., Murat, B., Kıvrak, T., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15049 · Cited by 21
How to Initiate and Uptitrate GDMT in Heart Failure
Bozkurt, B. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.005 · Cited by 21
SGLT2 inhibitors activate pantothenate kinase in the human heart
Forelli, N., Thome, T., Eaton, D., Schultz, K. C., Patel, J. D., Bowman, C. E., Kawakami, R., Jung, J. W., Kuznetsov, I. A., Li, K., et al. (2026) · Science · doi:10.1126/science.aeh4856 · Cited by 23
Garg, R., Sood, N., Bansal, O., & Hoskote, A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09073-2 · Cited by 23
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 26
Accelerating therapeutic discoveries for heart failure: a new public–private partnership
Shah, S. J., Butler, J., Shah, S. H., Kamphaus, T. N., & Sachdev, V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00158-3 · Cited by 20
Self-citationAcute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium
Amesz, J. H., Langmuur, S. J. J., Epskamp, N., Bogers, A. J. J. C., de Groot, N. M. S., Manintveld, O. C., & Taverne, Y. J. H. J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07434-3 · Cited by 20
Masuda, T., & Nagata, D. (2023) · Hypertension Research · doi:10.1038/s41440-023-01220-2 · Cited by 20
Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension
Nagai, M., Dote, K., & Förster, C. Y. (2023) · Hypertension Research · doi:10.1038/s41440-023-01272-4 · Cited by 21
Ageev, F. T., & Ovchinnikov, A. G. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2376 · Cited by 22
Stolfo, D., Lund, L. H., Sinagra, G., Lindberg, F., Dahlström, U., Rosano, G. M. C., & Savarese, G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad036 · Cited by 22
Müllens, W., Schulze, P. C., Westphal, J. G., Bogoviku, J., & Bauersachs, J. K. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad266 · Cited by 21
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Ali, A. E., Mazroua, M. S., ElSaban, M., Najam, N., Kothari, A. S., Mansoor, T., Amal, T., Lee, J., & Kashyap, R. (2023) · Global Heart · doi:10.5334/gh.1258 · Cited by 22
Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies
van de Veerdonk, M. C., Savarese, G., Handoko, M. L., Beulens, J. W. J., Asselbergs, F. W., & Uijl, A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00626-w · Cited by 21
Takizawa, D., Harada, T., Obokata, M., Kagami, K., Sorimachi, H., Yuasa, N., Saito, Y., Murakami, F., Naito, A., Kato, T., et al. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead242 · Cited by 20
Matsumoto, S., Kondo, T., Yang, M., Campbell, R. T., Docherty, K. F., de Boer, R. A., Desai, A. S., Lam, C. S. P., Packer, M., Pitt, B., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3044 · Cited by 22
Self-citationThe current best drug treatment for hypertensive heart failure with preserved ejection fraction
Rist, A., Sevre, K., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.008 · Cited by 23
Reyes-Farias, C. I., Reategui-Diaz, M., Romani-Romani, F., & Prokop, L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295059 · Cited by 20
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 22
Dhont, S., van den Acker, G. P. H., van Loon, T., Verbrugge, F. H., Verwerft, J., Deferm, S., Churchill, T. W., Müllens, W., Lumens, J., & Bertrand, P. B. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3231 · Cited by 20
Böhm, M., Butler, J., Coats, A. J. S., Lauder, L., Mahfoud, F., Filippatos, G. S., Ferreira, J. P., Pocock, S., Brueckmann, M., Hauske, S. J., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae938 · Cited by 20
Self-citationCVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 21
Self-citationSteven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 24
Pathophysiology of HFpEF: Insights from a Metabolic–Mitochondrial Perspective
Gatto, C., Rusciano, M. R., Visco, V., Vecchione, C., & Ciccarelli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010284 · Cited by 19
Heart Failure in Menopause: Treatment and New Approaches
da Silva, J. S., Montagnoli, T. L., de Sá, M. P. L., & Zapata‐Sudo, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315140 · Cited by 21
Katano, S., Yano, T., Kouzu, H., Nagaoka, R., Numazawa, R., Yamano, K., Fujisawa, Y., Ohori, K., Nagano, N., Fujito, T., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01727-x · Cited by 19
Mauro, C., Chianese, S., Cocchia, R., Arcopinto, M., Auciello, S., Capone, V., Carafa, M., Carbone, A., Caruso, G., Castaldo, R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030846 · Cited by 25
Treewaree, S., Kulthamrongsri, N., Owattanapanich, W., & Krittayaphong, R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1046194 · Cited by 23
Natriuretic Peptides in Clinical Practice: A Current Review
Lee, D. J. W., & Aw, T. C. (2023) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2023/1.1245 · Cited by 18
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 22
Pérez, M. S., Rodríguez‐Capitán, J., Requena-Ibáñez, J. A., Santos‐Gallego, C. G., Zafar, M. U., Escolar, G., MANCINI, D. M., Mitter, S. S., Lam, D. W.-H., Contreras, J., et al. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07469-6 · Cited by 19
Booth, D., Davis, J. A., McEwan, P. C., Solomon, S. D., McMurray, J. J. V., de Boer, R. A., Colet, J. C., Bachus, E., & Chen, J. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2940 · Cited by 24
Self-citationShi, Y., Liu, C., Xiong, S., Ling, Y., Yang, C., Qiao, W., Liu, Y., Liu, S., Liu, J., & Dong, G. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116849 · Cited by 19
Feng, B., Yu, P., Yu, H., Qian, B., Li, Y., Sun, K., Shi, B., Zhang, N., & Xu, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01116-8 · Cited by 19
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 19
Rees, O., Wheen, P., & Anderson, L. J. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-2023-23.5.cardio1 · Cited by 19
Lewis, G. D., GOSCH, K. L., COHEN, L. P., Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Khumri, T. M., Umpierrez, G. E., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010633 · Cited by 19
Self-citationHerzinsuffizienz: Leitlinien-Update der ESC 2023
Bauersachs, J. K., & Soltani, S. (2023) · Herz · doi:10.1007/s00059-023-05221-2 · Cited by 19
Neuen, B. L., Claggett, B. L., Perkovic, V., Jardine, M., Heerspink, H. J. L., Mahaffey, K. W., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2024) · Circulation · doi:10.1161/circulationaha.124.069382 · Cited by 19
Self-citationHarada, T., Naser, J. A., Tada, A., Doi, S., Ibe, T., Pislaru, S. V., Eleid, M. F., Sorimachi, H., Obokata, M., Reddy, Y. N. V., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3322 · Cited by 20
Reddy, Y. N. V., Noseworthy, P. A., Borlaug, B. A., & Albert, N. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.010 · Cited by 21
Camilli, M., Viscovo, M., Maggio, L., Bonanni, A., Torre, I., Pellegrino, C., Lamendola, P., Tinti, L., Teofili, L., Hohaus, S., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01059-9 · Cited by 19
Vecchia, G. L., Fumarulo, I., Caffè, A., Chiatto, M., Montone, R. A., & Aspromonte, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147628 · Cited by 20
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
